UNCONTROLLED WHEN PRINTED
Introduction
- A non-depolarising neuromuscular blocking agent
- Due to weak vagolytic action, a slight rise in pulse rate and MAP may be expected.
- Onset: 2-3 min, peak 8-10 min.
- Duration 30 min dose dependant
Indications
- To facilitate paralysis
- Maintain paralysis
Contraindications
- Hypersensitivity
Precautions / Notes
- Sedatives to be administered prior to Rocuronium Bromide unless patient hemodynamically unstable and performing crash intubation
- Continuous SpO2 and EtCO2 monitoring is a high priority
- Patients with Myasthenia Gravis should be given smaller doses and monitored carefully due to the potential of increased degree of neuromuscular block.
- Keep refrigerated at 2-8°C.
- Crash intubation preferred over Suxamethonium
Management
Critical Care Paramedic only
Adult/Paediatric:
- IV/IO
- Induction: 1.2mg/kg
- Initial dose: 0.6mg/kg (usually 50mg in adults) post Suxamethonium dose only
- Maintenance : 0.1-0.2mg/kg repeat PRN
- Infusion: 1.0mg/kg/hr
- Dilute 100mg in 10ml up to 100mg in 50ml with normal saline
- Induction: 1.2mg/kg
| Dose | 10kg | 20kg | 30kg | 40kg | 50kg | 60kg | 70kg | 80kg | 90kg | 100kg |
|---|---|---|---|---|---|---|---|---|---|---|
| 1mg/kg/hr | 5ml/hr | 10ml/hr | 15ml/hr | 20ml/hr | 25ml/hr | 30ml/hr | 35ml/hr | 40ml/hr | 45ml/hr | 50ml/hr |
Special Considerations
- Slight increase in pulse
- Slight increase in mean arterial pressure
References
References
Presentation
50mg in 5ml ampoule
Presentation image
| Colour assist: |
|---|
Document Control
Directorate
Clinical Services
Responsible Manager
Head of Clinical Services
Date of Issue
Date of Expiry
St John Ambulance Western Australia Ltd © Copyright 2020, All Rights Reserved